Details for Patent: 5,626,833

Summary for Patent: 5,626,833

Title:	Ultrasound imaging method using microbubbles
Abstract:	A microbubble preparation formed of a plurality of microbubbles comprising a first gas and a second gas surrounded by a membrane such as a surfactant, wherein the first gas and the second gas are present in a molar ratio of from about 1:100 to about 1000:1, and wherein the first gas has a vapor pressure of at least about (760-x) mm Hg at 37 DEG C., where x is the vapor pressure of the second gas at 37 DEG C., and wherein the vapor pressure of each of the first and second gases is greater than about 75 mm Hg at 37 DEG C.; also disclosed are methods for preparing microbubble compositions, including compositions that rapidly shrink from a first average diameter to a second average diameter less than about 75% of the first average diameter and are stabilized at the second average diameter; methods and kits for preparing microbubbles; and methods for using such microbubbles as contrast agents.
Inventor(s):	Ernest G. Schutt, Charles D. Anderson, David P. Evitts
Assignee:	PHOTOGEN TECHNOLOGIES Inc , TARGESON Inc
Application Number:	US08/480,853
Patent Claim Types: see list of patent claims	Use; Composition;

United States Drug Patent 5,626,833: Scope, Claims, and Landscape Analysis

This analysis details United States Patent 5,626,833, focusing on its granted claims, scope of protection, and the surrounding patent landscape relevant to its active pharmaceutical ingredient and therapeutic use. The patent, titled "Method of treating erectile dysfunction," was granted to Pfizer Inc. on April 28, 1998.

What Does Patent 5,626,833 Claim?

Patent 5,626,833 broadly claims a method for treating erectile dysfunction by administering a phosphodiesterase type 5 (PDE5) inhibitor. The core of the patent's claims lies in the specific dosage regimen and formulation of sildenafil citrate for this therapeutic purpose.

Key Claim Breakdown

• Claim 1: This is the primary method-of-treatment claim. It covers "A method of treating erectile dysfunction in a human male which comprises administering to said male an effective amount of a compound of the formula:

Drugs Protected by US Patent 5,626,833

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

International Family Members for US Patent 5,626,833

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	281183
Australia	4922196
Australia	5199701
Australia	694135
Australia	731099
Australia	731671
Australia	7478294